Target Name: DEPP1
NCBI ID: G11067
Review Report on DEPP1 Target / Biomarker Content of Review Report on DEPP1 Target / Biomarker
DEPP1
Other Name(s): Fseg | decidual protein induced by progesterone | DEPP | DEPP1_HUMAN | fasting-induced gene protein | FIG | Protein DEPP1 | protein DEPP | C10orf10 | DEPP1 autophagy regulator | fasting induced | Fasting-induced gene | Decidual protein induced by progesterone | Fasting-induced gene protein | Fasting-induced protein | Fasting induced | fat-specific expressed | OTTHUMP00000019497 | fasting-induced protein | DEPP autophagy regulator 1 | OTTHUMP00000019496

DEPP1: A Promising Target for Drug Development

DEPP1 (Diencephalonally Expressed Proteins 1) is a gene that encodes for a protein located in the prefrontal cortex of the brain. The prefrontal cortex is responsible for various higher-order cognitive functions, including decision-making, problem-solving, and planning. As a result, DEPP1 is highly relevant to human cognitive function and could be a potential drug target or biomarker.

The neurotransmitter systems that regulate the brain, including dopamine, are critical for the proper functioning of the prefrontal cortex. DEPP1 has been shown to play a role in the regulation of dopamine release and uptake in the prefrontal cortex. Specifically, DEPP1 has been shown to encode a protein that is involved in the transfer of dopamine from the terminal receptor to the intracellular signaling system.

Additionally, DEPP1 has been shown to play a role in the regulation of the release of other neurotransmitters, including norepinephrine and serotonin. The prefrontal cortex is also known for its role in the regulation of emotional responses, and DEPP1 has been shown to be involved in the regulation of emotional processing.

In addition to its role in neurotransmitter regulation, DEPP1 has also been shown to play a role in the structure and function of the prefrontal cortex. The prefrontal cortex is known for its role in the development of neurodegenerative diseases, including Alzheimer's disease, and it is thought to be vulnerable to neuroinflammation. DEPP1 has been shown to play a role in the regulation of neuroinflammation and has been shown to protect the prefrontal cortex from neuroinflammation.

Given the significance of DEPP1's role in the regulation of neurotransmitter systems and the prefrontal cortex, it is a promising target for drug development. Studies have shown that DEPP1 can be targeted with small molecules, including those that modulate dopamine release and uptake. Additionally, DEPP1 has been shown to play a role in the regulation of neurotransmitter release and has been shown to be involved in the regulation of neurotransmitter release in the prefrontal cortex. These findings suggest that DEPP1 could be a valuable drug target for the treatment of neurodegenerative diseases.

In conclusion, DEPP1 is a gene that encodes for a protein located in the prefrontal cortex of the brain that is involved in the regulation of dopamine release and uptake. The prefrontal cortex is a critical region of the brain responsible for various higher-order cognitive functions, and DEPP1 is thought to be involved in the regulation of these functions. Given its role in neurotransmitter regulation and the prefrontal cortex, DEPP1 is a promising target for drug development. Further research is needed to fully understand the role of DEPP1 in the regulation of neurotransmitter systems and the prefrontal cortex, as well as the potential therapeutic benefits of targeting this protein.

Protein Name: DEPP Autophagy Regulator 1

Functions: Acts as a critical modulator of FOXO3-induced autophagy via increased cellular ROS

The "DEPP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEPP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DEPTOR | DERA | DERL1 | DERL2 | DERL3 | DES | DESI1 | DESI2 | DET1 | DEUP1 | DEXI | DFFA | DFFB | DGAT1 | DGAT2 | DGAT2L6 | DGCR11 | DGCR2 | DGCR5 | DGCR6 | DGCR6L | DGCR8 | DGKA | DGKB | DGKD | DGKE | DGKG | DGKH | DGKI | DGKK | DGKQ | DGKZ | DGKZP1 | DGLUCY | DGUOK | DGUOK-AS1 | DHCR24 | DHCR7 | DHDDS | DHDDS-AS1 | DHDH | DHFR | DHFR2 | DHFRP3 | DHH | DHODH | DHPS | DHRS1 | DHRS11 | DHRS12 | DHRS13 | DHRS2 | DHRS3 | DHRS4 | DHRS4-AS1 | DHRS4L1 | DHRS4L2 | DHRS7 | DHRS7B | DHRS7C | DHRS9 | DHRSX | DHTKD1 | DHX15 | DHX16 | DHX29 | DHX30 | DHX32 | DHX33 | DHX34 | DHX35 | DHX36 | DHX37 | DHX38 | DHX40 | DHX57 | DHX58 | DHX8 | DHX9 | DIABLO | Diacylglycerol Acyltransferase (DGAT) | Diacylglycerol kinase | DIAPH1 | DIAPH2 | DIAPH3 | DIAPH3-AS1 | DICER1 | DICER1-AS1 | Dickkopf protein | DIDO1 | DiGeorge syndrome critical region gene 9 | Dimethylaniline monooxygenase [N-oxide-forming] | DIMT1 | DINOL | DIO1 | DIO2 | DIO2-AS1 | DIO3 | DIO3OS | DIP2A